Article ; Online: Sialyl-Tn serves as a potential therapeutic target for ovarian cancer.
2024 Volume 17, Issue 1, Page(s) 71
Abstract: Background: Ovarian cancer remains the deadliest of the gynecologic cancers in the United States. There have been limited advances in treatment strategies that have seen marked increases in overall survival. Thus, it is essential to continue developing ... ...
| Abstract | Background: Ovarian cancer remains the deadliest of the gynecologic cancers in the United States. There have been limited advances in treatment strategies that have seen marked increases in overall survival. Thus, it is essential to continue developing and validating new treatment strategies and markers to identify patients who would benefit from the new strategy. In this report, we sought to further validate applications for a novel humanized anti-Sialyl Tn antibody-drug conjugate (anti-STn-ADC) in ovarian cancer. Methods: We aimed to further test a humanized anti-STn-ADC in sialyl-Tn (STn) positive and negative ovarian cancer cell line, patient-derived organoid (PDO), and patient-derived xenograft (PDX) models. Furthermore, we sought to determine whether serum STn levels would reflect STn positivity in the tumor samples enabling us to identify patients that an anti-STn-ADC strategy would best serve. We developed a custom ELISA with high specificity and sensitivity, that was used to assess whether circulating STn levels would correlate with stage, progression-free survival, overall survival, and its value in augmenting CA-125 as a diagnostic. Lastly, we assessed whether the serum levels reflected what was observed via immunohistochemical analysis in a subset of tumor samples. Results: Our in vitro experiments further define the specificity of the anti-STn-ADC. The ovarian cancer PDO, and PDX models provide additional support for an anti-STn-ADC-based strategy for targeting ovarian cancer. The custom serum ELISA was informative in potential triaging of patients with elevated levels of STn. However, it was not sensitive enough to add value to existing CA-125 levels for a diagnostic. While the ELISA identified non-serous ovarian tumors with low CA-125 levels, the sample numbers were too small to provide any confidence the STn ELISA would meaningfully add to CA-125 for diagnosis. Conclusions: Our preclinical data support the concept that an anti-STn-ADC may be a viable option for treating patients with elevated STn levels. Moreover, our STn-based ELISA could complement IHC in identifying patients with whom an anti-STn-based strategy might be more effective. |
|---|---|
| MeSH term(s) | Humans ; Female ; Antigens, Tumor-Associated, Carbohydrate/metabolism ; CA-125 Antigen ; Ovarian Neoplasms ; Genital Neoplasms, Female ; Enzyme-Linked Immunosorbent Assay ; Biomarkers, Tumor |
| Chemical Substances | Antigens, Tumor-Associated, Carbohydrate ; CA-125 Antigen ; Biomarkers, Tumor |
| Language | English |
| Publishing date | 2024-04-02 |
| Publishing country | England |
| Document type | Journal Article |
| ZDB-ID | 2455679-8 |
| ISSN | 1757-2215 ; 1757-2215 |
| ISSN (online) | 1757-2215 |
| ISSN | 1757-2215 |
| DOI | 10.1186/s13048-024-01397-1 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.